Effectiveness of Corticosteroids in Treating Chemotherapy-Induced Thrombocytopenia
Researchers sought to determine whether corticosteroids would be an effective treatment for patients with chemotherapy-induced thrombocytopenia.
Diagnosis & Disease Information
Statin Use Linked to Reduced Risk for Intracerebral Hemorrhage
Risk reduced for lobar and nonlobar intracerebral hemorrhage; greater reductions seen with prolonged use ≥5 years
First Gene Therapy for Hemophilia B Gets FDA Approval
The approval was based on data from the HOPE-B trial that included 54 male participants with severe or moderately severe hemophilia B.
Once-Weekly Efanesoctocog Alfa Gets Priority Review for Hemophilia A
Efanesoctocog alfa is a novel recombinant factor VIII therapy designed to extend protection from bleeds by breaking the von Willebrand factor ceiling.
Rebinyn Approval for Hemophilia B Expanded to Include Routine Prophylaxis
Rebinyn is a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life.
Etranacogene Dezaparvovec, a Gene Therapy for Hemophilia B, Gets Priority Review
Etranacogene dezaparvovec is an investigational gene therapy that uses AAV5 to carry the Padua gene variant of factor IX.
Efgartigimod Looks Promising for Primary Immune Thrombocytopenia
The phase 3 ADVANCE trial evaluated the efficacy and safety of efgartigimod in 131 adults with primary ITP.
Apixaban Tied to Lower Risk for Recurrent VTE in Dialysis Population
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
ACC: Bleeding Risk Lower With Tranexamic Acid in Noncardiac Surgery
But, though difference is small, tranexamic acid not noninferior to placebo for primary safety outcome of composite cardiovascular outcome
Gene Therapy Gets Fast Track Status for Hemophilia A
In preclinical studies, ASC618 has been shown to have at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered constructs.
